Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Lynparza TM

Listen to the Pronunciation:

Active ingredients: olaparib

What it is used for

Ovarian cancer,LYNPARZA is indicated as monotherapy for the:, maintenance treatment of adult patients with advanced breast cancer susceptibility gene (BRCA) mutated (germline or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. BRCA mutation status should be determined by an experienced laboratory using a validated test method., maintenance treatment of adult patients with platinum-sensitive relapsed high grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) after platinum-based chemotherapy. Prior treatment must have included at least 2 courses of platinum-based regimens.,Lynparza in combination with bevacizumab is indicated for the:, maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: a deleterious or suspected deleterious BRCA mutation (germline or somatic), and/or; genomic instability,HRD status should be determined by an experienced laboratory using a validated test method.,Breast cancer,LYNPARZA is indicated as monotherapy for the:, treatment of adult patients with germline BRCA-mutated HER2-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Germline BRCA mutation (gBRCAm) status should be determined by an experienced laboratory using a validated test method.,Adenocarcinoma of the pancreas,Lynparza is indicated as monotherapy for the:, maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Germline BRCA mutation (gBRCAm) status should be determined by an experienced laboratory using a validated test method.,Prostate cancer,LYNPARZA is indicated as monotherapy for the:, treatment of adult patients with BRCA-mutated (germline and/or somatic) metastatic castration-resistant prostate cancer who have progressed following prior therapy that included a new hormonal agent. BRCA mutation status should be determined by an experienced laboratory using a validated test method.

How to take it

The way to take this medicine is: Oral. This medicine is taken by mouth.

  • Store below 30 degrees Celsius
  • Protect from Moisture
  • Store in Original Container
  • Shelf lifetime is 4 Years.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.

Visual appearance

Green to green/grey film-coated, oval, biconvex tablet, debossed with 'OP 150' on one side and plain on the reverse

Images are the copyright of the Pharmacy Guild of Australia

Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.

Is this medicine subsidised?

This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on August 1, 2022. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.

Pregnant or planning a pregnancy?

For the active ingredient olaparib

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Consumer Medicines Information (CMI)

For side effects, taking other medicines and more

Print the CMI.

Listen to the CMI.


Reporting side effects

You can help ensure medicines are safe by reporting the side effects you experience.

You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems

Back to top back to top

Healthdirect 24hr 7 days a week hotline

24 hour health advice you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information and advice

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Victorian government logo Government of Western Australia, health department logo

Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and present.